← Eichor
Condition: Normal Subjects Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Normal Subjects

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 · 40 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06625775Pharmacokinetics of VC005 Tablets in Subjects With Hepatic Impairment and Normal Hepatic Function
Phase 1 · 1 location(s) · Jiangsu vcare pharmaceutical technology co., LTD · NCT07551557Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
Phase 1 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT05083754US Zamto-cel Autoimmune Diseases
Phase 1 · 1 location(s) · Miltenyi Biomedicine GmbH · NCT06708845Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
Phase 1 · 3 location(s) · HC Biopharma Inc. · NCT06657703A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1 · 14 location(s) · CRISPR Therapeutics · NCT06925542Study of XB010 in Subjects With Solid Tumors
Phase 1 · 20 location(s) · Exelixis · NCT06545331Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
Phase 1 · 2 location(s) · Chipscreen Biosciences, Ltd. · NCT06902350Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT05366179Optic Nerve Head Strain in Non-glaucoma Subjects
EARLY_Phase 1 · 1 location(s) · Johns Hopkins University · NCT07425535Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06347068A Study of ST-1898 for Unresectable or Metastatic Melanoma
Phase 1/Phase 2 · 1 location(s) · Beijing Scitech-Mq Pharmaceuticals Limited · NCT06359860HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT06769425A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria
NA · 1 location(s) · Sirt3 LLC · NCT07471048BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Phase 1/Phase 2 · 25 location(s) · BioInvent International AB · NCT04752826Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subj
Phase 1 · 1 location(s) · Wright State University · NCT04520217Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Canc
Phase 2 · 1 location(s) · RemeGen Co., Ltd. · NCT06642545A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Krystal Biotech, Inc. · NCT05970497Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associat
Phase 1 · 1 location(s) · Akros Pharma Inc. · NCT07247266RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic
Phase 1/Phase 2 · 23 location(s) · Cabaletta Bio · NCT06121297Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Ma
Phase 2 · 1 location(s) · John Waters · NCT07039526Efficacy Evaluation and Cutaneous Acceptibility of a Dermocosmetic Product on Subjects Suffering of Atopic Dermatisis.
NA · 1 location(s) · NAOS Les Laboratoires · NCT06756438Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
Phase 1/Phase 2 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT01799538Peri-Implant Soft Tissue Integration in Humans: Influence of Material
NA · 1 location(s) · Centre Hospitalier Universitaire de Liege · NCT05805033A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT
Phase 2 · 5 location(s) · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · NCT05171894A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Phase 1/Phase 2 · 4 location(s) · OncoResponse, Inc. · NCT06090266Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or
Phase 3 · 88 location(s) · Daiichi Sankyo · NCT05950945A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin)
Phase 1/Phase 2 · 58 location(s) · Eisai Inc. · NCT04300556A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
Phase 1/Phase 2 · 19 location(s) · Nkarta, Inc. · NCT06557265APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 2 · 35 location(s) · Apollomics Inc. · NCT03175224
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.